Surgical oncology | 2021
Comorbid depression in surgical cancer patients associated with non-routine discharge and readmission.
Abstract
OBJECTIVE\nTo characterize the rates of depression across primary cancer sites, and determine the effects of comorbid depression among surgical cancer patients on established quality of care indicators, non-routine discharge and readmission.\n\n\nMETHODS\nPatients undergoing surgical resection for cancer were selected from the Nationwide Readmissions Database (2010-2014). Multivariable analysis adjusted for patient and hospital level characteristics to ascertain the effect of depression on post-operative outcomes and 30-day readmission rates. Non-routine discharge encompasses discharge to skilled nursing, inpatient rehabilitation, and intermediate care facilities, as well as discharge home with home health services.\n\n\nRESULTS\nAmong 851,606 surgically treated cancer patients, 8.1% had a comorbid diagnosis of depression at index admission (n\xa0=\xa069,174). Prevalence of depression was highest among patients with cancer of the brain (10.9%), female genital organs (10.9%), and lung (10.5%), and lowest among those with prostate cancer (4.9%). Depression prevalence among women (10.9%) was almost twice that of men (5.7%). Depression was associated with non-routine discharge after surgery (OR 1.20, CI:1.18-1.23, p\xa0<\xa00.0001*) and hospital readmission within 30 days (OR 1.12, CI:1.09-1.15, p\xa0<\xa00.001*).\n\n\nCONCLUSION\nRates of depression vary amongst surgically treated cancer patients by primary tumor site. Comorbid depression in these patients is associated with increased likelihood of non-routine discharge and readmission.